Revision of Applications for Manufacturing and Procurement Quotas
DEA proposes to revise regulations for manufacturing and procurement quotas for schedule I/II controlled substances and list I chemicals, affecting application processes and management.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Manufacturers and procurers of schedule I/II controlled substances and list I chemicals, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends [date not specified in excerpt; check Federal Register for exact date].. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Proposed revisions to existing regulations on how applications for manufacturing and procurement quotas are submitted and managed, potentially altering timelines, documentation, and approval criteria.
Who it affects
Manufacturers and procurers of schedule I/II controlled substances and list I chemicals, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B).
What you must do
Review the proposed rule in detail and prepare to adjust quota application processes to align with new requirements once finalized.
Deadline
Comment period ends [date not specified in excerpt; check Federal Register for exact date].
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments
- Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
- Designation of P2P Methyl Glycidic Acid as a List I Chemical
- Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
- Exempt Chemical Preparations Under the Controlled Substances Act